Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab as Single Agent and in Combination With Obinutuzumab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT03075696Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2017
- Primary completion
- Mar 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, open-label trial of glofitamab in non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities at 4 weeks, Percentage of Participants With Adverse Events up to 5 years and 9 more. Started Feb 2017; status: active, not recruiting.
02
Drugs
glofitamab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03075696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075696.